Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 1:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 74 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Late initiation Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Early Initiation of Milk Expression in Mothers of Very Low Birth Weight Infants

NCT01892085
View directory record Official record
Conditions
Breast Milk Expression
Interventions
Early initiation, Intermediate expression, Late initiation
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Sep 5, 2026, 1:37 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Epidermal Growth Factor Receptor Inhibition for Keratinopathies

NCT06545695
View directory record Official record
Conditions
Epidermolytic Ichthyosis, Palmoplantar Keratoderma, Pachyonychia Congenita
Interventions
Erlotinib
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 5, 2026, 1:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Southwest Hub for American Indian Youth Suicide Prevention Research

NCT03543865
View directory record Official record
Conditions
Suicide, Surveillance, Mental Health, Substance Use, Depressive Symptoms
Interventions
New Hope (NH), Elders Resilience (ER), Case Management (CM)
Behavioral · Other
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
16 Years to 29 Years
Enrollment
304 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Whiteriver, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 5, 2026, 1:37 PM EDT
Completed Not applicable Interventional

Effects of Breathwork and Meditation on Addiction Recovery

NCT07510256
View directory record Official record
Conditions
Addiction, Addiction Disorders
Interventions
SKY Breathing Program
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Sanborn, New York
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Sep 5, 2026, 1:37 PM EDT
Completed Not applicable Interventional

Streamlined Treatment of Pulmonary Exacerbations in Pediatrics Pilot Study

NCT04608019
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Immediate Antibiotics, Tailored Treatment
Other
Lead sponsor
University of Washington, the Collaborative Health Studies Coordinating Center
Other
Eligibility
6 Years to 18 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Tucson, Arizona • Aurora, Colorado • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Sep 5, 2026, 1:37 PM EDT
Terminated Phase 2 Interventional Results available

Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer

NCT00611858
View directory record Official record
Conditions
Rectal Cancer
Interventions
Cetuximab, 5-Fluorouracil, Radiation
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
4
States / cities
Boston, Massachusetts • Weymouth, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Sep 5, 2026, 1:37 PM EDT
Completed No phase listed Observational

Improvement in Endothelial Dysfunction After Initiation of Anti-arrhythmic Therapy in Atrial Fibrillation Patients

NCT04128878
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Sotalol, Dofetilide
Drug
Lead sponsor
Samir Saba
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Timeline
2019 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Sep 5, 2026, 1:37 PM EDT
Not yet recruiting Phase 4 Interventional

Ketamine for the Treatment of Refractory Status Epilepticus

NCT07177235
View directory record Official record
Conditions
Refractory Status Epilepticus
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 5, 2026, 1:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

HCV and Co-morbid Alcohol Use Disorders: A Translational Investigation of Antiviral Therapy Outcomes on CNS Function

NCT03902366
View directory record Official record
Conditions
Hepatitis C, Alcohol Use Disorder
Interventions
Neuropsychological assessment, Neuroimaging
Diagnostic Test · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Sep 5, 2026, 1:37 PM EDT
Terminated Not applicable Interventional Results available

Horyzons: Implementation and Integration in Clinical Practice

NCT06002958
View directory record Official record
Conditions
Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorder, Unspecified or Other Psychotic Disorders
Interventions
Horyzons USA
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 35 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Sep 5, 2026, 1:37 PM EDT
Recruiting Not applicable Interventional

ONC-LEUK-2406: The Impact of Systematic Financial Navigation in Acute Myeloid Leukemia

NCT06945042
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Arm A, Arm B
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 64 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Charlotte, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 5, 2026, 1:37 PM EDT
Withdrawn Phase 2 Interventional

Study of Metformin With Simvastatin for Men With Prostate Carcinoma

NCT01561482
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Metformin, Simvastatin
Drug
Lead sponsor
Nicholas Mitsiades
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2015 · Synced Sep 5, 2026, 1:37 PM EDT
Recruiting Early Phase 1 Interventional

Single Arm Romiplostim to Prevent CIT

NCT07048249
View directory record Official record
Conditions
Ewings Sarcoma, Chemotherapy Induced Thrombocytopenia
Interventions
Romiplostim (AMG-531)
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Year and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Phoenix, Arizona • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 5, 2026, 1:37 PM EDT
Terminated Phase 4 Interventional Results available

Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia

NCT00712270
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole, Risperidone
Drug
Lead sponsor
Kettering Health Network
Other
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Kettering, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Sep 5, 2026, 1:37 PM EDT
Recruiting Phase 1Phase 2 Interventional

Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant

NCT06129734
View directory record Official record
Conditions
Myeloid Malignancy, Acute Myeloid Leukemia
Interventions
Venetoclax, Decitabine
Drug
Lead sponsor
Benjamin Tomlinson
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 5, 2026, 1:37 PM EDT
Completed Phase 1 Interventional

Vemurafenib and Panitumumab Combination Therapy in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer

NCT01791309
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
combination panitumumab and vemurafenib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2016 · Synced Sep 5, 2026, 1:37 PM EDT
Not yet recruiting Not applicable Interventional

Health Enhanced Artery Risk Tracking With Widespread Implementation and Screening Effort in ASCVD (HEARTWISE-ASCVD)

NCT07355894
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD), Coronary Artery Calcification
Interventions
AI-Detected CAC Notification and Care Facilitation
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 74 Years
Enrollment
120,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Pleasanton, California • Stanford, California + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 5, 2026, 1:37 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Population Health Management -Increase Lung Cancer Screening in Community Health Centers (LungSMART)

NCT07599943
View directory record Official record
Conditions
Lung Cancer
Interventions
Text Messages (TM+), Chatbot (CA), Video (VID), Reactive Patient Navigation (RPN), Proactive Patient Navigation (PPN)
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
50 Years to 80 Years
Enrollment
18,894 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 5, 2026, 1:37 PM EDT
Completed Phase 4 Interventional Results available

Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis

NCT00179478
View directory record Official record
Conditions
Multiple Sclerosis, Optic Neuritis, Transverse Myelitis, Acute Brainstem/Cerebellar Syndrome
Interventions
interferon beta 1a 30 ug IM once weekly
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
20
States / cities
Derby, Connecticut • Tampa, Florida • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Sep 5, 2026, 1:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

SweetMama: Testing of a Novel Technology for Diabetes Education and Support to Pregnant Women

NCT03240874
View directory record Official record
Conditions
Diabetes Mellitus in Pregnancy
Interventions
SweetMama Focus Groups, SweetMama Individual Testing, SweetMama Feasibility Testing - Pilot Randomized Trial
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Sep 5, 2026, 1:37 PM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

NCT03013998
View directory record Official record
Conditions
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177)
Biological · Other · Drug
Lead sponsor
Beat AML, LLC
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2032
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 5, 2026, 1:37 PM EDT
Recruiting Not applicable Interventional

Streamlined Treatment of Pulmonary Exacerbations in Pediatrics

NCT06654752
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Immediate Oral Antibiotics, Tailored Treatment: Oral Antibiotics only if Additional Treatment needed
Other
Lead sponsor
University of Washington, the Collaborative Health Studies Coordinating Center
Other
Eligibility
3 Years to 18 Years
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
31
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 5, 2026, 1:37 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00085254
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
Interventions
cilengitide, temozolomide, radiation therapy, laboratory biomarker analysis, pharmacological study
Drug · Radiation · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
8
States / cities
Birmingham, Alabama • Atlanta, Georgia • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced Sep 5, 2026, 1:37 PM EDT
Active, not recruiting Phase 3 Interventional

Recovery Management Checkups for Opioid Use Disorder Experiment

NCT04365920
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Recovery Management Checkups (RMC), RMC-Adaptive
Combination Product
Lead sponsor
Chestnut Health Systems
Other
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Sep 5, 2026, 1:37 PM EDT